Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Exocrine Pancreatic Insufficiency (EPI): later-stage trial registry

1 of 1 indexed Exocrine Pancreatic Insufficiency (EPI) trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Exocrine Pancreatic Insufficiency (EPI): 1 US clinical trial tracked, 1 recruiting.

Exocrine Pancreatic Insufficiency (EPI) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 1 of these trials.

Enrollment posture brief

Registry condition exocrine-pancreatic-insufficiency-epi

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Exocrine Pancreatic Insu (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Exocrine Pancreatic Insufficiency (EPI)

Exocrine Pancreatic Insufficiency (EPI) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Exocrine Pancreatic Insufficiency (EPI) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Exocrine Pancreatic Insufficiency (EPI) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Exocrine Pancreatic Insufficiency (EPI) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RELiZORB Device
1 trials

US sites by state

Facility locations filed on Exocrine Pancreatic Insufficiency (EPI) trials. A trial with sites in several states counts in each.

Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Exocrine Pancreatic Insufficiency (EPI) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Exocrine Pancreatic Insufficiency (EPI) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Massachusetts General Hospital sponsors the most Exocrine Pancreatic Insufficiency (EPI) trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Exocrine Pancreatic Insufficiency (EPI) condition card totals 1 registered trials; most-linked intervention RELiZORB; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.